This study is looking at how a dietary supplement called β-hydroxy β-methyl butyrate (HMB) might help people who have both alcoholic liver disease (ALD) and COVID-19 pneumonia. HMB is a substance that can help build muscle. Researchers want to see if HMB can prevent breathing problems and improve recovery for these patients. You might be able to join if you are 21 or older, have ALD (diagnosed by clinical, imaging, lab, or biopsy results) and COVID-19 pneumonia, and meet specific liver health criteria (Child Pugh score 5-8, serum creatinine <3, MELD score <25). The study will measure changes in muscle mass and the number of hospital admissions over 90 days to see if the supplement is helpful. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll 48 participants. It compares a dietary supplement called β-hydroxy β-methyl butyrate (HMB) enriched amino acid with a balanced amino acid supplement.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 90 days after starting the study to measure changes in muscle mass and hospital admissions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.